MISSION

GamaMabs is a clinical-stage immuno-oncology biotech developing first-in-class optimized antibodies targeting AMHRII, a new tumor antigen expressed in many cancers such as ovarian, cervix, colorectal, lung, renal, endometrium and liver cancers.

TECHNOLOGY

GamaMabs has patents and rights on immuno-enhancing technologies for antibodies, and on AMHRII, a new tumor antigen. Its lead project is GM102 currently tested in phase 1b/2a trials in solid tumors. The company also develops an ADC in collaboration with Medimmune, in preclinical stage.

COMPETITION

CSF1R and CD47-targeted programs

ALLIANCES/PARTNERSHIPS

License and collaboration agreement with Medimmune for the development of an ADC

UPCOMING CATALYSTS

Early June: publication of initial results of C101 study in gynecological cancers at ASCO
June: Initiation of phase 2a study in metastatic colorectal cancer (“C201 study”)
Q4 2018: Completion of C101 study
Q4 2018: Completion of recruitment in C201 study
Q4 2018 / 1Q 2019: series-C financing

KEY FIGURES

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>Growth (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EBIT</td>
<td>(4.2)</td>
<td>(7.5)</td>
<td>+79%</td>
</tr>
<tr>
<td>Net Income</td>
<td>(3.1)</td>
<td>(5.6)</td>
<td>+80%</td>
</tr>
<tr>
<td>Cash Position</td>
<td>1.3</td>
<td>4.5</td>
<td>+246%</td>
</tr>
</tbody>
</table>
**GAMAMABS PHARMA**

**NAME OF THE CEO**
Stéphane DEGOVE

---

**SHARHOLDERS**

- Management and Directors: 16%
- LFB: 16%
- Investors: 68%

**PIPELINE**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug class / Target</th>
<th>Development stage</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM102</td>
<td>mAb / AMHRII</td>
<td>Phase 1b/2a</td>
<td>Gynecological cancers and mCRC</td>
</tr>
<tr>
<td>GM104</td>
<td>ADC / undisclosed</td>
<td>Preclinical</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>9F7</td>
<td>HER3-targeted mAb</td>
<td>Preclinical</td>
<td>Solid tumors</td>
</tr>
</tbody>
</table>

**ADDRESS**
Centre Pierre Potier
1 place Pierre Potier
31106 Toulouse Cedex 1

**EMAIL**
sdegove@gamamabs.com
www.gamamabs.com

**MANAGEMENT TEAM**
CEO: Stéphane Degove
CMO: Dr. Isabelle Tabah-Fisch
CSO: Dr. Jean-François Prost

**TARGETED MARKET**

solid tumors, gynecological and colorectal cancers as 1st targeted indications

**PRIVATE COMPANY**

**CREATION DATE**
June 2013